肺癌中的免疫疗法。
Immunotherapy in lung cancer.
作者信息
Al-Moundhri M, O'Brien M, Souberbielle B E
出版信息
Br J Cancer. 1998 Aug;78(3):282-8. doi: 10.1038/bjc.1998.486.
Abstract
More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology. In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct therapeutic action on all subtypes of lung cancer.
摘要
肺癌各个阶段都需要更多的研究和新的治疗选择。鉴于最近技术的改进以及对潜在生物学的更深入理解，免疫疗法需要复兴。在这篇综述中，我们讨论肿瘤免疫疗法的机制，包括非特异性、特异性和过继性免疫疗法，特别提及对肺癌所有亚型的直接治疗作用。
相似文献
1
Immunotherapy in lung cancer.肺癌中的免疫疗法。
Br J Cancer. 1998 Aug;78(3):282-8. doi: 10.1038/bjc.1998.486.
2
Immunotherapy of lung cancer: a review.肺癌的免疫治疗：综述
Int Adv Surg Oncol. 1983;6:229-56.
3
BCG, levamisole and transfer factor in the treatment of cancer.卡介苗、左旋咪唑及转移因子在癌症治疗中的应用
Prog Exp Tumor Res. 1980;25:178-92. doi: 10.1159/000403181.
4
Surgical adjuvant immunotherapy for lung cancer: a review.肺癌的手术辅助免疫治疗：综述
Curr Surg. 1984 Jul-Aug;41(4):254-61.
5
Immunotherapy of lung cancer. I. Review of clinical trials in non-small cell histologic types.肺癌的免疫疗法。I. 非小细胞组织学类型临床试验综述
Cancer Treat Rev. 1979 Sep;6(3):177-90. doi: 10.1016/s0305-7372(79)80069-9.
6
[Clinical trials of immunotherapy in lung cancer].[肺癌免疫治疗的临床试验]
Wiad Lek. 1984 Jul 1;37(13):997-1003.
7
[Immunotherapy and urological malignancy].[免疫疗法与泌尿系统恶性肿瘤]
Nihon Hinyokika Gakkai Zasshi. 1991 Mar;82(3):361-71. doi: 10.5980/jpnjurol1989.82.361.
8
[Current trends in immunotherapy of tumors of the lung].[肺癌免疫治疗的当前趋势]
Arch Monaldi. 1983 Jan-Apr;38(1-2):41-52.
9
[Immunotherapy of carcinoma of the lung].[肺癌的免疫治疗]
Recenti Prog Med. 1978 Mar;64(3):293-309.
10
[Significance of immunotherapy as an adjunct to surgical treatment in non-small cell carcinoma of the lung].[免疫疗法作为肺癌非小细胞癌手术治疗辅助手段的意义]
Gan To Kagaku Ryoho. 1985 Jan;12(1):13-20.
引用本文的文献
1
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date.帕博利珠单抗治疗非小细胞肺癌的聚焦：迄今的证据
Onco Targets Ther. 2016 Sep 23;9:5855-5866. doi: 10.2147/OTT.S97746. eCollection 2016.
2
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?PD-L1 生物标志物检测在非小细胞肺癌中的应用：是真是假？
J Immunother Cancer. 2016 Aug 16;4:48. doi: 10.1186/s40425-016-0153-x. eCollection 2016.
3
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.基于PD-1的疗法的临床应用：聚焦派姆单抗（MK-3475）在黑色素瘤及其他肿瘤类型治疗中的应用
Onco Targets Ther. 2015 Apr 22;8:929-37. doi: 10.2147/OTT.S53164. eCollection 2015.
4
Immunologic and clinical effects of targeting PD-1 in lung cancer.靶向 PD-1 在肺癌中的免疫和临床效应。
Clin Pharmacol Ther. 2014 Aug;96(2):214-23. doi: 10.1038/clpt.2014.74. Epub 2014 Apr 1.
5
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.肺癌：肿瘤逃逸与进展的经典范例，同时也为免疫干预提供了契机。
Clin Dev Immunol. 2012;2012:160724. doi: 10.1155/2012/160724. Epub 2012 Jul 29.
6
Activation of innate immunity to reduce lung metastases in breast cancer.激活固有免疫以减少乳腺癌肺转移。
Cancer Immunol Immunother. 2010 May;59(5):789-97. doi: 10.1007/s00262-009-0800-x. Epub 2009 Dec 3.
7
Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses.树突状细胞能有效地获取并呈递源自肺癌细胞的抗原，并诱导抗原特异性T细胞反应。
Cancer Immunol Immunother. 2003 Jul;52(7):413-22. doi: 10.1007/s00262-003-0382-y. Epub 2003 Feb 15.
8
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.一项关于SRL172（母牛分枝杆菌）联合化疗用于晚期不可手术非小细胞肺癌和间皮瘤患者的随机II期研究。
Br J Cancer. 2000 Oct;83(7):853-7. doi: 10.1054/bjoc.2000.1401.
本文引用的文献
1
Pulmonary perspective: immunology in diagnosis and treatment of lung cancer.肺部视角：免疫学在肺癌诊断与治疗中的应用
Eur Respir J. 1997 Aug;10(8):1703-19. doi: 10.1183/09031936.97.10081703.
2
Tumor antigens recognized by T cells.被T细胞识别的肿瘤抗原。
Immunol Today. 1997 Jun;18(6):267-8. doi: 10.1016/s0167-5699(97)80020-5.
3
The Th1/Th2 paradigm.Th1/Th2模式。
Immunol Today. 1997 Jun;18(6):263-6. doi: 10.1016/s0167-5699(97)80019-9.
4
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.用B7.1和白细胞介素-2转导的经辐照的NC腺癌细胞可诱导CD4 +介导的对已形成肿瘤的排斥反应。
Hum Gene Ther. 1997 Mar 1;8(4):477-88. doi: 10.1089/hum.1997.8.4-477.
5
Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients.重组腺病毒介导的基因转移在肺癌患者中的I期研究。
J Natl Cancer Inst. 1996 Dec 18;88(24):1857-63. doi: 10.1093/jnci/88.24.1857.
6
Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274).用重组腺病毒H5.010RSVTK治疗晚期间皮瘤：一项1期试验（BB-IND 6274）。
Hum Gene Ther. 1996 Oct 20;7(16):2047-57. doi: 10.1089/hum.1996.7.16-2047.
7
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.黑色素瘤细胞中Fas（Apo-1/CD95）配体的表达：对肿瘤免疫逃逸的影响。
Science. 1996 Nov 22;274(5291):1363-6. doi: 10.1126/science.274.5291.1363.
8
Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer.II期和IIIA期原发性肺癌根治性切除术后的辅助化疗免疫治疗。
Lung Cancer. 1996 Jun;14(2-3):301-14. doi: 10.1016/0169-5002(96)00555-7.
9
Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene.在免疫功能正常的大鼠模型中利用腺病毒介导单纯疱疹病毒胸苷激酶基因转移治疗胸膜间皮瘤。
Hum Gene Ther. 1996 Jan 20;7(2):141-8. doi: 10.1089/hum.1996.7.2-141.
10
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.逆转录病毒介导的野生型p53基因向肺癌患者肿瘤的转移。
Nat Med. 1996 Sep;2(9):985-91. doi: 10.1038/nm0996-985.
Zotero 插件